老年早期乳腺癌标准辅助化疗对比卡培他滨的10年随机试验更新
CALGB 49907试验针对65岁及以上早期乳腺癌女性,随机比较标准辅助化疗(CMF或AC方案)与卡培他滨。
要点
- 总生存无显著差异,老年人群竞争风险稀释生存获益。
核心结论
- 中位随访11.4年,标准辅助化疗较卡培他滨持续显著改善无复发生存,尤其在激素受体阴性患者中。
- 总生存获益被老年人群竞争风险稀释,两组间无显著差异。
研究设计与样本
- 随机对照试验,纳入633例65岁及以上早期乳腺癌患者,随机分配至标准辅助化疗(CMF或AC方案)或卡培他滨。
- 采用适应性贝叶斯设计确定样本量并检验卡培他滨的非劣效性,主要终点为无复发生存。
主要发现
- 43.9%患者死亡(13.1%死于乳腺癌,16.4%死于非乳腺癌原因,14.1%死因未知),14.1%发生第二非乳腺癌。
临床怎么用
- 对于65岁及以上早期乳腺癌患者,标准辅助化疗(CMF或AC方案)仍应优先考虑,尤其激素受体阴性者。
- 卡培他滨不宜替代标准辅助化疗用于该人群的常规治疗。
- 临床决策需综合评估竞争风险,向患者说明总生存获益可能被非乳腺癌死亡稀释。
局限性
- 研究仅纳入65岁及以上女性,结果不能外推至年轻患者。
- 标准化疗组为医生选择的CMF或AC方案,未区分具体方案效应。
- 总生存差异不显著,可能受样本量和竞争风险影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Older women with breast cancer remain under-represented in clinical trials. The Cancer and Leukemia Group B 49907 trial focused on women age 65 years and older. We previously reported the primary analysis after a median follow-up of 2.4 years. Standard adjuvant chemotherapy showed significant improvements in recurrence-free survival (RFS) and overall survival compared with capecitabine. We now update results at a median follow-up of 11.4 years. PATIENTS AND METHODS: Patients age 65 years or older with early breast cancer were randomly assigned to either standard adjuvant chemotherapy (physician's choice of either cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide and doxorubicin) or capecitabine. An adaptive Bayesian design was used to determine sample size and test noninferiority of capecitabine. The primary end point was RFS. RESULTS: The design stopped accrual with 633 patients at its first sample size assessment. RFS remains significantly longer for patients treated with standard chemotherapy. At 10 years, in patients treated with standard chemotherapy versus capecitabine, the RFS rates were 56% and 50%, respectively (hazard ratio [HR], 0.80; P = .03); breast cancer-specific survival rates were 88% and 82%, respectively (HR, 0.62; P = .03); and overall survival rates were 62% and 56%, respectively (HR, 0.84; P = .16). With longer follow-up, standard chemotherapy remains superior to capecitabine among hormone receptor-negative patients (HR, 0.66; P = .02), but not among hormone receptor-positive patients (HR, 0.89; P = .43). Overall, 43.9% of patients have died (13.1% from breast cancer, 16.4% from causes other than breast cancer, and 14.1% from unknown causes). Second nonbreast cancers occurred in 14.1% of patients. CONCLUSION: With longer follow-up, RFS remains superior for standard adjuvant chemotherapy versus capecitabine, especially in patients with hormone receptor-negative disease. Competing risks in this older population dilute overall survival benefits.
引用
- Muss HB, Polley MC, Berry DA, et al. Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. J Clin Oncol. 2019. PMID: 31339827. doi:10.1200/JCO.19.00647
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。